Full Text Available

Note: Clicking the button above will open the full text document at the original institutional repository in a new window.

The development of a ZnO nanoforce biosensor for mortalin - a novel biomarker for Parkinson’s Disease

Thesis (MEng)--Stellenbosch University, 2022.

Saved in:
Bibliographic Details
Main Author: Naicker, Semai
Other Authors: Perold, Willem
Format: Thesis
Language:en_ZA
Published: Stellenbosch : Stellenbosch University 2022
Subjects:
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1867613898909155328
access_status_str Open Access
author Naicker, Semai
author2 Perold, Willem
author_browse Naicker, Semai
Perold, Willem
author_facet Perold, Willem
Naicker, Semai
author_sort Naicker, Semai
collection Thesis
dc_rights_str_mv Stellenbosch University
description Thesis (MEng)--Stellenbosch University, 2022.
format Thesis
id oai:scholar.sun.ac.za:10019.1/124630
institution Stellenbosch University (South Africa)
language en_ZA
last_indexed 2026-06-10T12:43:27.297Z
license_str Other — see source repository
provenance_str_mv Harvested via OAI-PMH from SUNScholar — Stellenbosch University Repository
publishDate 2022
publishDateRange 2022
publishDateSort 2022
publisher Stellenbosch : Stellenbosch University
publisherStr Stellenbosch : Stellenbosch University
record_format dspace
source_str SUNScholar — Stellenbosch University Repository
spelling oai:scholar.sun.ac.za:10019.1/124630 The development of a ZnO nanoforce biosensor for mortalin - a novel biomarker for Parkinson’s Disease Naicker, Semai Perold, Willem Stellenbosch University. Faculty of Engineering. Dept. of Electrical and Electronic Engineering. UCTD Biomarkers Parkinson's disease -- Diagnosis Nanowire-array biosensor Biosensor industry Thesis (MEng)--Stellenbosch University, 2022. ENGLISH ABSTRACT: Parkinson’s disease, affecting 0.5 to 1% of persons aged 65 to 69 and up to 3% of persons aged 80 and older [1], is currently incurable. The typical diagnosis of Parkinson’s disease is performed clinically, after the onset of symptoms, which means that progressive symptoms must be controlled, as opposed to the possibility of prevention of symptoms. Mortalin protein, a participant in various essential physiological functions, has been found to be down-regulated in the blood serum of Parkinson’s disease patients and can be identified as an indicative biomarker for Parkinson’s. With a biosensor for Mortalin, the antigen’s concentration levels can be detected from early life stages. This introduces the prospect of preventative measures being put into place, to reduce the severity of Parkinson’s disease symptoms that may develop at a later stage. Therefore, the aim of this thesis was to develop a biosensor with the ability to detect the concentration levels of Mortalin in a biological sample. This was achieved through the development of a ZnO nanowire-based nanoforce biosensor. An electrochemical deposition process, for the deposition of well-aligned, c-axis orientated nanowires on Silicon substrates, was optimised. The nanowire array was further developed into a ZnO nanowire-based nanogenerator, and anti-Mortalin antibodies were immobilised onto the surface, using a Cysteamine self-assembled monolayer and a Glutaraldehyde cross-linker. The final biosensor was realised by addition of an electronic measurement system, in the form of signal amplification and appropriate conditioning, to reduce noise and amplify the small signals generated by the nanowires. The nanoforce biosensor was tested with biological samples (solutions of Mortalin antigen in PBS) of different concentrations, and the response of the biosensor, due to the addition of each sample, was recorded. The changes in voltage, observed in the different responses, were compared and it was found that the magnitude of the response correlates with the Mortalin concentration level in the biological sample, although no clear proportionality was observed. Therefore, it was concluded that the Mortalin nanoforce biosensor was successfully able to detect the Mortalin antigen concentration. However, further testing needs to be performed to determine the relationship between the voltage response and the Mortalin concentration. AFRIKAANSE OPSOMMING: Geen behandeling bestaan tans vir Parkinson-siekte nie, wat 0.5 tot 1% van alle mense tussen die ouderdom van 65 en 69, en 3% van dié ouer as 80, affekteer. Die siekte word huidiglik slegs klinies gediagnoseer na die aanvang van simptome. Dit was onlangs bevind dat mortalien, ’n proteïen wat in menigde noodsaaklike fisio logiese prosesse deelneem, afgereguleer word in die bloed serum van diegene met Parkinson-siekte, asook dat dit as ’n voorspellende biomerker gebruik kan word vir die diagnose van Parkinson-siekte. Die doel van hierdie tesis was om ’n biosensor te ontwikkel om die konsentrasie van mortalien in ’n biologiese monster te meet. Hierdie doel was bewerkstellig deur die gebruik van ’n sinkoksied nanodraad-gebaseerde biosensor. Om so sensor te ontwikkel, was ’n elektrochemiese proses aanvanklik geoptimeer vir die groei van belynde, c-as geörienteerde, nanodrade op ’n intrinsieke silikon substraat. Om die vervaardigde nanodrade as biosensor te gebruik, was dit in ’n nanogenerator omgeskakel deur teenliggaampies op die nanodrade te immobiliseer deur middel van ’n sisteamien self-georganiseerde monolaag en glutaaraldehied kruiskoppeling. Verder, was die finale biosensor gerealiseer deur die gebruik van elektroniese meet komponente, in die vorm van seinversterking en gepaste kondisionering om ontslae te raak van ruis en die bruikbare sein na vore te bring uit die lae potensiaalverskille geïnduseer deur hierdie soort nanogenerator. Die bogenoemde biosensor het daarin geslaag om die konsentrasie van mortalien in biologiese monsters in beplande toetse te meet. Masters 2022-03-02T05:16:53Z 2022-04-29T09:23:12Z 2022-03-02T05:16:53Z 2022-04-29T09:23:12Z 2022-04 Thesis http://hdl.handle.net/10019.1/124630 en_ZA Stellenbosch University 149 pages application/pdf Stellenbosch : Stellenbosch University
spellingShingle UCTD
Biomarkers
Parkinson's disease -- Diagnosis
Nanowire-array biosensor
Biosensor industry
Naicker, Semai
The development of a ZnO nanoforce biosensor for mortalin - a novel biomarker for Parkinson’s Disease
title The development of a ZnO nanoforce biosensor for mortalin - a novel biomarker for Parkinson’s Disease
title_full The development of a ZnO nanoforce biosensor for mortalin - a novel biomarker for Parkinson’s Disease
title_fullStr The development of a ZnO nanoforce biosensor for mortalin - a novel biomarker for Parkinson’s Disease
title_full_unstemmed The development of a ZnO nanoforce biosensor for mortalin - a novel biomarker for Parkinson’s Disease
title_short The development of a ZnO nanoforce biosensor for mortalin - a novel biomarker for Parkinson’s Disease
title_sort development of a zno nanoforce biosensor for mortalin a novel biomarker for parkinson s disease
topic UCTD
Biomarkers
Parkinson's disease -- Diagnosis
Nanowire-array biosensor
Biosensor industry
url http://hdl.handle.net/10019.1/124630
work_keys_str_mv AT naickersemai thedevelopmentofaznonanoforcebiosensorformortalinanovelbiomarkerforparkinsonsdisease
AT naickersemai developmentofaznonanoforcebiosensorformortalinanovelbiomarkerforparkinsonsdisease